Lyfaquin (Centhaquine) Injection
Lyfaquin is indicated as a resuscitative agent for the treatment of patients with hypovolemic shock as an adjuvant to standard of care. Lyfaquin ® uniquely stimulates α2B adrenergic receptors to increase venous blood return and cardiac output; and on α2A adrenergic receptors to decrease vascular resistance, thereby enhancing tissue blood perfusion. It is a key improvement over current therapy by complementing with standard of care. Salt Composition – Centhaquine Injection (Brand name Lyfaquin) is available in Delhi, India. Product Name Lyfaquin Salt Composition Centhaquine Injection Product Form / Net Quantity Lyfaquin ® injection is a sterile preparation of 1.0 mg centhaquine citrate intended for intravenous use. The product is available as 10 mL amber tubular glass vial. Marketed By Dr.
About Lyfaquin (Centhaquine) Injection
Description Centhaquine is a frontline therapy used along with the standard of care and is well positioned to a critical unmet need as a pharmacologically active resuscitative agent. A decrease in the volume of blood circulation from blood or fluid loss due to trauma, gastrointestinal bleeding, major surgery, postpartum hemorrhage, diarrhea, or vomiting can cause hypovolemic shock. About 1.9 million people worldwide die because of hemorrhagic shock every year, most dying within the first 6 hours. Centhaquine activates venous alpha2B adrenergic receptors to increase cardiac preload and activates central alpha2A adrenergic receptors to decrease cardiac afterload. Thereby, Centhaquine converts the venous unstressed blood volume to stressed blood volume and improves cardiac output and blood circulation, making it an ideal candidate for the resuscitation of patients with hypovolemic shock. Centhaquine was approved in India by Drugs Controller General of India following a successful phase III clinical trial. The results of are published in a manuscript entitled “A Multicentric, Randomized, Controlled Ph III Study of Centhaquine (Lyfaquin®), as a Resuscitative Agent in Hypovolemic Shock Patients”. The manuscript is published in DRUGS and is available at: https://link.springer.com/article/10.1007/s40265-021-01547-5 Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatation. Who is the CFA, distributor, and retailer for Lyfaquin (Centhaquine) Injection in India? Lyfaquin (Centhaquine) Injection are managed and supplied in India through Aark Pharmaceuticals, the authorised and government-approved CFA, distributor, and retailer. Lyfaquin (Centhaquine) Injection are available across India on request, with access in major cities including Delhi, Gurgaon, Noida, Kanpur, Mumbai, Indore, Kolkata, Ludhiana, Hyderabad, Kochi, Bengaluru, Vijayawada, Chennai, Bhopal, Pune, Nashik, Lucknow, Madurai, Ahmedabad, Vadodara, Patna, Prayagraj (Allahabad), Jaipur, Meerut, Agra, Jabalpur, Varanasi, Visakhapatnam, Coimbatore, Asansol, Nagpur, and Surat. How much do Lyfaquin Injection cost in Delhi, India? Prices may vary based on your prescribed treatment plan. For accurate and the most cost-effective pricing on your prescription-recommended product, please contact Aark Pharmaceuticals Seller Name: Aark Pharmaceuticals Private Limited. Contact Person: Ms. Himanshi Address: S-14, Ground & Ist Floor, Green Park Extn., New Delhi-110016. Mobile / WhatsApp : 9999156233 Email: sales@aarkpharma.co.in , sales@aarkpharma.com Our Branch Offices in India – New Delhi | Lucknow | Varanasi | Chandigarh | Kolkata | Patna | Jodhpur. Do you offer any discounts? Yes. Based on availability, prices may vary based on your prescribed treatment plan. Please ask for the best current price. Prior to consuming an
